Investment Recommendations for Zoetis and Energy Transfer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: CNBC
- Zoetis Investment Warning: Zoetis's performance has raised concerns, with analysts expressing a preference for Elanco for the first time, indicating potential challenges for Zoetis in the animal health sector that could impact market confidence and stock performance.
- Energy Transfer Investment Opportunity: Energy Transfer is viewed as a highly attractive investment option, with analysts noting its undervalued stock price and good dividend yield, likely appealing to investors seeking stable income.
- Market Sentiment Shift: The contrasting negative outlook for Zoetis and positive sentiment for Energy Transfer reflects differing expectations in the market, which may lead investors to reassess their portfolios.
- Long-term Investment Strategy: Jim Cramer recommends focusing on Energy Transfer's investment potential, emphasizing its undervalued status and stable dividend yield, which could provide investors with long-term wealth growth opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 77.590
Low
130.00
Averages
154.20
High
200.00
Current: 77.590
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zoetis Releases 2025 Sustainability Report Highlighting Key Achievements
- Sustainability Goals Achieved: The Zoetis Foundation successfully distributed $35 million in grants from 2021 to 2025, supporting veterinary professionals and livestock farmers while advancing humanitarian aid, showcasing the company's commitment to social responsibility.
- Innovative Vaccine Approvals: The company received conditional licenses for its H5N2 vaccine in the U.S. and Canada to combat avian influenza in poultry and dairy cattle, marking Zoetis's scientific innovation capabilities and market leadership in animal health.
- Significant Emission Reductions: Since 2021, Zoetis has reduced its Scope 1 and 2 emissions by 29%, completing over 100 carbon reduction projects in 2025 alone, which are expected to prevent approximately 5,000 metric tons of CO2e annually, reflecting the company's strong commitment to environmental sustainability.
- Volunteer Service Exceeded Goals: In 2025, employees reported over 20,700 hours of volunteer time, exceeding the company's stated goal by 104%, demonstrating Zoetis's success in promoting employee engagement in social responsibility initiatives.
See More
Screwworm Fears Spark Market Activity for Zoetis and Elanco
- Market Reaction: The discovery of New World screwworm in Texas has led to shares of Zoetis and Elanco Animal Health rising nearly 4% and 2% respectively on Thursday, indicating strong market interest in animal health products.
- Surge in Options Trading: Options volume for Zoetis surged to almost 20 times the daily average, with nearly 12,000 contracts traded, including the purchase of 4,200 call options, reflecting investor optimism about the company's future performance.
- FDA Support: Zoetis received conditional FDA approval last year for an injectable product that treats and prevents reinfestation of the screwworm, and last month the FDA issued emergency use authorization, bolstering market confidence in the product.
- Beef Supply Risks: While cattle futures are up over 1%, the potential spread of the screwworm could strain beef supply, leading to market volatility among American consumers who favor fast food, highlighting the economic implications of this event.
See More
Dow Jones Hits All-Time High Amid Mixed Market Performance
- Dow Jones High: The Dow Jones Industrial Average surged 1.49% to reach a new all-time high, demonstrating market resilience driven by strong performance in managed healthcare stocks, despite overall market pressures.
- Tech Sector Decline: Broadcom's stock plummeted over 14% due to disappointing AI revenue forecasts, leading to a broader decline in chipmakers, while CrowdStrike fell more than 8% despite beating Q1 earnings expectations, reflecting market caution towards tech stocks.
- Mixed Economic Data: Initial jobless claims rose to 225,000, a 3.75-month high, indicating a weaker labor market, while Q1 nonfarm productivity was revised down to 0.3%, below expectations, potentially impacting future economic growth outlooks.
- Oil Price Impact: WTI crude oil prices fell over 3% amid a ceasefire agreement between Israel and Lebanon, which lowered inflation expectations and provided support for both stock and bond markets, improving investor sentiment.
See More
Zoetis Faces Class Action Lawsuit from Investors
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Zoetis Inc., alleging violations of federal securities laws on behalf of all investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, inclusive.
- False Statements Allegation: The complaint claims that Zoetis made materially false and misleading statements regarding the growth and market share of its Companion Animal products, failing to disclose significant declines in veterinarian adoption of Librela and Simparica Trio, leading to substantial investor losses.
- Competitive Pressure: Following FDA safety warnings, the growth in veterinarian prescriptions for Librela sharply weakened, while Simparica Trio lost significant market share to a lower-priced competitor, indicating a slowdown in the overall market.
- Investor Action Recommendation: Affected investors have until July 27, 2026, to request lead plaintiff status, with Bronstein, Gewirtz & Grossman LLC operating on a contingency fee basis, ensuring that investor rights are upheld in the process.
See More
Zoetis Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Zoetis in the Southern District of New York on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, to apply as lead plaintiff.
- Allegation Details: The lawsuit alleges that Zoetis failed to disclose significant adverse facts about its business, including weakening prescription growth for Librela and significant market share loss for Simparica Trio, misleading investors about the company's prospects.
- Market Impact: Following FDA safety warnings, veterinarians have become more cautious in prescribing Librela, which may negatively impact Zoetis's stock price and investor confidence, leading to potential financial losses.
- Legal Consultation Opportunity: Affected investors are encouraged to contact the law firm for more information regarding their legal rights and potential claims, with no cost for initial consultations offered.
See More
Investment Recommendations for Zoetis and Energy Transfer
- Zoetis Investment Warning: Zoetis's performance has raised concerns, with analysts expressing a preference for Elanco for the first time, indicating potential challenges for Zoetis in the animal health sector that could impact market confidence and stock performance.
- Energy Transfer Investment Opportunity: Energy Transfer is viewed as a highly attractive investment option, with analysts noting its undervalued stock price and good dividend yield, likely appealing to investors seeking stable income.
- Market Sentiment Shift: The contrasting negative outlook for Zoetis and positive sentiment for Energy Transfer reflects differing expectations in the market, which may lead investors to reassess their portfolios.
- Long-term Investment Strategy: Jim Cramer recommends focusing on Energy Transfer's investment potential, emphasizing its undervalued status and stable dividend yield, which could provide investors with long-term wealth growth opportunities.
See More
Zoetis Releases 2025 Sustainability Report Highlighting Key Achievements
- Sustainability Goals Achieved: The Zoetis Foundation successfully distributed $35 million in grants from 2021 to 2025, supporting veterinary professionals and livestock farmers while advancing humanitarian aid, showcasing the company's commitment to social responsibility.
- Innovative Vaccine Approvals: The company received conditional licenses for its H5N2 vaccine in the U.S. and Canada to combat avian influenza in poultry and dairy cattle, marking Zoetis's scientific innovation capabilities and market leadership in animal health.
- Significant Emission Reductions: Since 2021, Zoetis has reduced its Scope 1 and 2 emissions by 29%, completing over 100 carbon reduction projects in 2025 alone, which are expected to prevent approximately 5,000 metric tons of CO2e annually, reflecting the company's strong commitment to environmental sustainability.
- Volunteer Service Exceeded Goals: In 2025, employees reported over 20,700 hours of volunteer time, exceeding the company's stated goal by 104%, demonstrating Zoetis's success in promoting employee engagement in social responsibility initiatives.
See More
Screwworm Fears Spark Market Activity for Zoetis and Elanco
- Market Reaction: The discovery of New World screwworm in Texas has led to shares of Zoetis and Elanco Animal Health rising nearly 4% and 2% respectively on Thursday, indicating strong market interest in animal health products.
- Surge in Options Trading: Options volume for Zoetis surged to almost 20 times the daily average, with nearly 12,000 contracts traded, including the purchase of 4,200 call options, reflecting investor optimism about the company's future performance.
- FDA Support: Zoetis received conditional FDA approval last year for an injectable product that treats and prevents reinfestation of the screwworm, and last month the FDA issued emergency use authorization, bolstering market confidence in the product.
- Beef Supply Risks: While cattle futures are up over 1%, the potential spread of the screwworm could strain beef supply, leading to market volatility among American consumers who favor fast food, highlighting the economic implications of this event.
See More
Dow Jones Hits All-Time High Amid Mixed Market Performance
- Dow Jones High: The Dow Jones Industrial Average surged 1.49% to reach a new all-time high, demonstrating market resilience driven by strong performance in managed healthcare stocks, despite overall market pressures.
- Tech Sector Decline: Broadcom's stock plummeted over 14% due to disappointing AI revenue forecasts, leading to a broader decline in chipmakers, while CrowdStrike fell more than 8% despite beating Q1 earnings expectations, reflecting market caution towards tech stocks.
- Mixed Economic Data: Initial jobless claims rose to 225,000, a 3.75-month high, indicating a weaker labor market, while Q1 nonfarm productivity was revised down to 0.3%, below expectations, potentially impacting future economic growth outlooks.
- Oil Price Impact: WTI crude oil prices fell over 3% amid a ceasefire agreement between Israel and Lebanon, which lowered inflation expectations and provided support for both stock and bond markets, improving investor sentiment.
See More
Zoetis Faces Class Action Lawsuit from Investors
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Zoetis Inc., alleging violations of federal securities laws on behalf of all investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, inclusive.
- False Statements Allegation: The complaint claims that Zoetis made materially false and misleading statements regarding the growth and market share of its Companion Animal products, failing to disclose significant declines in veterinarian adoption of Librela and Simparica Trio, leading to substantial investor losses.
- Competitive Pressure: Following FDA safety warnings, the growth in veterinarian prescriptions for Librela sharply weakened, while Simparica Trio lost significant market share to a lower-priced competitor, indicating a slowdown in the overall market.
- Investor Action Recommendation: Affected investors have until July 27, 2026, to request lead plaintiff status, with Bronstein, Gewirtz & Grossman LLC operating on a contingency fee basis, ensuring that investor rights are upheld in the process.
See More
Zoetis Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Zoetis in the Southern District of New York on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, to apply as lead plaintiff.
- Allegation Details: The lawsuit alleges that Zoetis failed to disclose significant adverse facts about its business, including weakening prescription growth for Librela and significant market share loss for Simparica Trio, misleading investors about the company's prospects.
- Market Impact: Following FDA safety warnings, veterinarians have become more cautious in prescribing Librela, which may negatively impact Zoetis's stock price and investor confidence, leading to potential financial losses.
- Legal Consultation Opportunity: Affected investors are encouraged to contact the law firm for more information regarding their legal rights and potential claims, with no cost for initial consultations offered.
See More
Investment Recommendations for Zoetis and Energy Transfer
- Zoetis Investment Warning: Zoetis's performance has raised concerns, with analysts expressing a preference for Elanco for the first time, indicating potential challenges for Zoetis in the animal health sector that could impact market confidence and stock performance.
- Energy Transfer Investment Opportunity: Energy Transfer is viewed as a highly attractive investment option, with analysts noting its undervalued stock price and good dividend yield, likely appealing to investors seeking stable income.
- Market Sentiment Shift: The contrasting negative outlook for Zoetis and positive sentiment for Energy Transfer reflects differing expectations in the market, which may lead investors to reassess their portfolios.
- Long-term Investment Strategy: Jim Cramer recommends focusing on Energy Transfer's investment potential, emphasizing its undervalued status and stable dividend yield, which could provide investors with long-term wealth growth opportunities.
See More
